- Home
- CLBR vs LXEO Comparison
CLBR vs LXEO Comparison
Compare CLBR & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLBR
- LXEO
- Stock Information
- Founded
- CLBR 2023
- LXEO 2017
- Country
- CLBR United States
- LXEO United States
- Employees
- CLBR N/A
- LXEO N/A
- Industry
- CLBR
- LXEO
- Sector
- CLBR
- LXEO
- Exchange
- CLBR Nasdaq
- LXEO Nasdaq
- Market Cap
- CLBR 240.1M
- LXEO 252.4M
- IPO Year
- CLBR 2023
- LXEO 2023
- Fundamental
- Price
- CLBR $11.59
- LXEO $6.75
- Analyst Decision
- CLBR
- LXEO Strong Buy
- Analyst Count
- CLBR 0
- LXEO 5
- Target Price
- CLBR N/A
- LXEO $23.80
- AVG Volume (30 Days)
- CLBR 286.4K
- LXEO 258.3K
- Earning Date
- CLBR 01-01-0001
- LXEO 12-24-2024
- Dividend Yield
- CLBR N/A
- LXEO N/A
- EPS Growth
- CLBR N/A
- LXEO N/A
- EPS
- CLBR N/A
- LXEO N/A
- Revenue
- CLBR N/A
- LXEO N/A
- Revenue This Year
- CLBR N/A
- LXEO N/A
- Revenue Next Year
- CLBR N/A
- LXEO N/A
- P/E Ratio
- CLBR $152.01
- LXEO N/A
- Revenue Growth
- CLBR N/A
- LXEO N/A
- 52 Week Low
- CLBR $9.16
- LXEO $5.77
- 52 Week High
- CLBR $12.28
- LXEO $22.33
- Technical
- Relative Strength Index (RSI)
- CLBR 75.88
- LXEO 43.67
- Support Level
- CLBR $11.50
- LXEO $6.77
- Resistance Level
- CLBR $12.28
- LXEO $7.40
- Average True Range (ATR)
- CLBR 0.29
- LXEO 0.65
- MACD
- CLBR 0.06
- LXEO -0.01
- Stochastic Oscillator
- CLBR 77.38
- LXEO 21.76
About CLBR Colombier Acquisition Corp. II
Colombier Acquisition Corp II is a blank check company.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.